Reducing low-density lipoprotein cholesterol levels lowers the risk of atherosclerotic cardiovascular disease. With the current and future portfolios of emerging lipid-lowering therapies included in various national and international guidelines, the objectives of this study were (i) to investigate the perceptions of UK prescribers’, including doctors, pharmacists, and nurses, on current lipid management for cardiovascular diseases and prescriptions of novel lipid-lowering therapies, and (ii) to explore the challenges and facilitating factors of prescribing novel lipid-lowering therapies through qualitative interviews. Qualitative semi-structured interviews with twelve medical and non-medical prescribers were conducted, around 20–30 min in length. The interviews were audio-recorded and transcribed on an online platform. A thematic analysis was deployed. Four major themes emerged from the analysis: (1) prescribing barriers; (2) prescribing enablers; (3) inter-profession variability; and (4) health literacy. These themes highlighted the contrast between the need for optimal shared decision making and the various constraints in practice. Participants expressed their inexperience with novel lipid-lowering therapies and acknowledged the requirement and importance of these agents for primary cardiovascular disease prevention. Participants recognised confidence and competence as key drivers for prescribing therapies and welcomed further education and training to enhance their skillset. Patients’ misconceptions towards current lipid-lowering therapies contributed to their refusal of newer agents, highlighting a requirement to improve patient education. Targeting communities through awareness campaigns was identified as a viable solution.
Background: Cardiovascular disease is a leading cause of mortality in England, with South Asians estimated to have a higher risk of CVD development compared to the general population. Harmful drinking is a key risk factor for cardiovascular disease, but little is known about drinking behaviours among South Asians, especially those aged 18–25. Objectives: The objectives of this study were (i) to investigate the knowledge of the cardiovascular effects of harmful drinking among young South Asians aged 18–25, and (ii) to explore the perceptions of young South Asians towards the role of the pharmacist in supporting individuals with alcohol-related harm. Methods: Qualitative, in depth, face-to-face, semi-structured interviews were conducted with ten young South Asians, around 30 min in length. The interviews were audio recorded, transcribed verbatim and then thematically analysed. Results: Four superordinate themes emerged: (1) Culture Clash; (2) The Great Escape; (3) Cardiovascular Confusion; and (4) The Ambiguous Pharmacist. These themes highlighted a dichotomy between the drinking behaviours among different South Asian communities, a lack of knowledge regarding the cardiovascular consequences of harmful drinking and mixed views regarding pharmacists’ role in supporting dependence. Participants acknowledged the prevalence of poor cardiovascular health among British South Asians, citing various types of dysfunction and possible causes; however, the effect of drinking specifically was not understood. Most participants would refer a young person struggling with dependence to a pharmacist and would be receptive to discussing drinking with one. However, few commented on any role outside of signposting to other services or healthcare providers. Conclusions: Greater cardiovascular health promotion is needed among South Asians, with an emphasis on the link between excess alcohol consumption and cardiovascular dysfunction. Furthermore, pharmacists must do more to promote greater awareness of the different ways in which alcohol dependence can be supported within the community to encourage young people seeking harm reduction to utilise those services as needed.